Differential expression of inducible nitric oxide synthase and peroxisome proliferator-activated receptor gamma in non-small cell lung carcinoma

References 

1. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis. 1998;19:711–721
   • MEDLINE
2. Debril MB, Renaud JP, Fajas L, Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J Mol Med. 2001;79:30–47
   • MEDLINE
3. Wright JL, Dai J, Zay K, Price K, Gilks CB, Churg A. Effects of cigarette smoke on nitric oxide synthase expression in the rat lung. Lab Invest. 1999;79:975–983
   • MEDLINE
4. Lee RP, Wang D, Kao SJ, Chen HI. The lung is the major site that produces nitric oxide to induce acute pulmonary oedema in endotoxin shock. Clin Exp Pharmaco Physiol. 2001;28:315–320
5. Jaiswal M, LaRusso NF, Burgart U, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000;60:184–190
   • MEDLINE
6. Boyle P, Maisonneuve P. Lung cancer and tobacco smoking. Lung Cancer. 1995;12:167–181
   • Abstract
   • Full-Text PDF (1189 KB)
7. Liu CY, Wang CH, Chen TC, Lin HC, Yu CT, Kuo HP. Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. Br J Cancer. 1998;78:534–541
   • MEDLINE
8. Fujimoto H, Sasaki J, Matsumoto M, Suga M, et al.  Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma. Jpn J Cancer Res. 1998;89:696–702
   • MEDLINE
9. Ambs S, Bennett WP, Merriam WG, et al.  Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer. 1998;78:233–239
   • MEDLINE
10. Marrogi AJ, Travis WD, Welsh JA, et al.  Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res. 2000;6:4739–4744
    • MEDLINE
11. Eibl G, Wente MN, Reber HA, Hines OJ. Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis. Biochem Biophys Res Commun. 2001;287:522–529
    • MEDLINE
12. Gupta RA, Brockman JA, Sarraf P, Wilison TM, DuBois RN. Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem. 2001;276:29681–29687
    • MEDLINE
13. Tsubouchi Y, Sano H, Kawahito Y, et al.  Inhibition of human lung cancer cell growth by the peroxisome proliferatoractivated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun. 2000;270:400–405
    • MEDLINE
14. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res. 2000;60:1129–1138
    • MEDLINE
15. Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol. 2000;20:4699–4707
    • MEDLINE
16. Liang YC, Tsai SH, Tsai DC, Lin-Shiau SY, Lin JK. Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferatoractivated receptor-gamma by flavonoids in mouse macrophages. FEBS Lett. 2000;496:12–18
    • Abstract
    • Full Text
    • Full-Text PDF (305 KB)
17. Fahmi H, Di Battista JA, Pelletier JP, Mineau F, Ranger P, Martel-Pelletier J. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheumatism. 2001;44:595–607
18. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79–82
    • MEDLINE
19. Chen G, Wang SH, Warner TD. Regulation of iNOS mRNA levels in endothelial cells by glutathione, a double-edged sword. Free Rad Res. 2000;32:223–234
20. Mukhopadhyay T, Roth JA, Maxwell SA. Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene. 1995;11:999–1003
    • MEDLINE
21. Emmendoerffer A, Hecht M, Boeker T, Mueller M, Heinrich U. Role of inflammation in chemical-induced lung cancer. Toxicol Lett. 2000;112–113:185–191
22. Scott FM, Prime W, Walshaw M, Turnbull L, Field JK. Peptide amidating activity in human bronchoalveolar lavage fluid (relationship to lung cancer, inflammation and infection). International Journal of Oncology. 2000;16:327–332
    • MEDLINE
23. Haugen A, Ryberg D, Mollerup S, Zienolddiny S, Skaug V, Svendsrud DH. Gene-environment interactions in human lung cancer. Toxicol Lett. 2000;112–113:233–237
24. Bogdan C. Nitric oxide and the immune response. Nat Immunol. 2001;2:907–916
    • MEDLINE
25. Gallo O, Masini E, Morbidelli L, et al.  Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst. 1998;90:587–596
    • MEDLINE
26. Burney S, Caulfield JL, Niles JC, Wishnok JS, Tannenbaum SR. The chemistry of DNA damage from nitric oxide and peroxynitrite. Mutation Res. 1999;424:37–49
27. Huang LC, Clarkin KC, Wahl GM. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci. 1996;93:4827–4832